The candidates for such mitogenic mediators are the members of FGF family, such as FGF1, FGF2, FGF9 and FGF18
 Human genes: FGF2, fibroblast growth factor 2 (basic); FGF1, fibroblast growth factor 1 (acidic); FGF7, fibroblast growth factor 7; FGFR1, fibroblast growth factor receptor1; FGF18, fibroblast growth factor 18; FGF23, fibroblast growth factor 23; FGF5, fibroblast growth factor 5; FGFR2, fibroblast growth factor receptor 2; FGFR4, fibroblast growth factor receptor 4; FGF14, fibroblast growth factor 14; FGF9, fibroblast growth factor 9; FGF10, fibroblast growth factor 10.
Nonresponders SNP Gene Position (ww/wv/vv) (a) rs3806929 FGF18 5' Flanking region 42/45/9 rs9920722 FGF7 Intron 47/42/7 rs12812339 FGF23 5' Flanking region 55/34/7 rs3733336 FGF5 3' UTR 37/49/10 Responders SNP (ww/wv/vv) OR (95%CI) (b) P Model (c) rs3806929 66/92/41 0.64 (0.44-0.94) 0.022 Add (d) rs9920722 71/99/29 0.65 (0.44-0.98) 0.039 Add rs12812339 92/83/22 0.65 (0.43-0.98) 0.039 Add rs3733336 71/92/36 0.44 (0.19-0.98) 0.045 Rec (a) ww, homozygous for wild-type allele; wv, heterozygous for variant allele; vv, homozygous for variant allele; OR, odds ratio; UTR, untranslated region.
These findings suggest that additional studies on the predictive potential FGF18
and its use as a therapeutic target in ovarian cancer should be conducted.
During the thickening of the prospective tooth region epithelium which then forms the dental lamina, the expressions of Fgf10 and Fgf18 are found in the mesenchyme [63, 65].
In the mesenchyme during these stages, FGF4, FGF8, and FGF20 bind to FGFR1IIIc while FGF4, FGF8, FGF9, FGF16, FGF18, and FGF20 bind to FGFR2IIIc [64, 65].
At this stage, FGF18 is expressed in the mesenchyme, except for the region underneath the epithelium of the tooth bud.
During development, endogenous Fgf18 is known to play an important role in skeletal growth as indicated by malformations of caldaria suture and growth plate in mice lacking FGF18 [7,8].
In this study, we hypothesized that FGF18 could enhance the trophic effects of MSC when cocultured with chondrocytes derived from late stage OA patients.
For pellet coculture, 100 000 chondrocytes and 100 000 MSC (ratio of 1:1) were seeded in one well of a round bottom ultralow attachment 96-well plate in serumfree medium with or without FGF18 (10 ng/mL) and centrifuged for 3 min at 500 xg.
Serum-free medium with or without FGF18 (10ng/mL) was used.
Constructs were cultured in serum-free medium with or without FGF18 (10ng/mL) for 2 weeks before being implanted into nude mice subcutaneously.